Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
ERAS-601, a potential best-in-class SHP2 inhibitor, is being investigated alone and in combination in the ongoing FLAGSHP-1 Phase 1/1b trial Erasca previously signed CTCSAs with Lilly and...
-
SAN DIEGO, June 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
-
SAN DIEGO, June 02, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
-
Shannon Morris, M.D., Ph.D., appointed as Senior Vice President of Clinical Development Amy Grekowicz Parker appointed as Vice President of Clinical Operations John Lo, Ph.D., appointed as Senior...
-
Presented compelling preclinical data at 2022 AACR Annual Meeting supporting clinical development of potentially best-in-class programs Initial Phase 1b monotherapy data for ERAS-007 and Phase 1...
-
SAN DIEGO, May 03, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for...
-
SAN DIEGO, April 27, 2022 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies...
-
ERAS-007 is a potent and selective small molecule ERK1/2 inhibitor with long target residence time, which promotes sustained RAS/MAPK pathway inhibition ERAS-601 is a potent and selective small...
-
Virtual event on Tuesday, April 12 at 4:30 PM ET will feature key opinion leader (KOL) Scott Kopetz, M.D., Ph.D., from MD Anderson Cancer Center Company and KOL to discuss an overview of unmet...
-
Five ongoing clinical trials evaluating candidates ERAS-007 (ERKi), ERAS-601 (SHP2i), and ERAS-801 (CNS-penetrant EGFRi) Initial Phase 1b data for HERKULES-1 and Phase 1 data for FLAGSHP-1 expected...